{
    "nctId": "NCT05939310",
    "briefTitle": "Fluorescence Guided Surgery in Breast Cancer - The MARGIN-2 Study",
    "officialTitle": "Improving Radical Resection Rates in Patients With Breast Cancer by Intraoperative Imaging Using Bevacizumab-IRDye800CW - the MARGIN-2 Study",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Breast Cancer Invasive",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 70,
    "primaryOutcomeMeasure": "Detection",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients are females with histologically proven carcinoma of the breast\n* The carcinoma of the breast is a local disease with limited size (but tumor size \u2265 0.5cm) and in the multidisciplinary tumor board meeting breast conserving therapy is advised.\n* Age \u2265 18 years\n* Written informed consent has been obtained\n* Women of childbearing potential (premenopausal women with intact reproductive organs and women less than two years after menopause) require use of effective contraception at least 3 months before administration of the tracer (if not, a negative serum pregnancy test has to be submitted), and they need to be willing to ensure that she or her partner uses effective contraception during the trial and for 3 months thereafter.\n\nExclusion Criteria:\n\n* Medical or psychiatric conditions that compromise the patient's ability to give informed consent\n* Non palpable breast tumor or prior surgery of this breast\n* Received an investigational drug within 30 days prior to bevacizumab-IRDye800CW\n* History of myocardial infarction, cerebrovascular accident, uncontrolled cardiac heart failure or unstable angina within 6 months prior to enrollment\n* Inadequately controlled hypertension with or without current antihypertensive medication\n* Significant renal or hepatic impairment (grade II or higher deviations by CTCAE)\n* History of allergy or infusion reactions bevacizumab or other monoclonal antibodies\n* Pregnant or lactating women\n* Patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents\n* Life expectancy \\< 12 weeks\n* Preoperatively undetectable lymph nodes using SPECT-scan, requiring the use of patent blue",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}